Skip to main content
Year archive

Akeso, Inc. — 2020 filings

All 67 regulatory filings released by Akeso, Inc. (9926) in 2020, sourced directly from the official regulator.

67 Filings
2020 Period
2020 filings (67)
Filing Released Lang
VOLUNTARY ANNOUNCEMENT - GRANT OF RSUs PURSUANT TO THE RESTRICTED SHARE UNIT SCHEME
Regulatory Filings
2020-12-21 English
CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
Regulatory Filings
2020-12-14 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2020
Regulatory Filings
2020-12-03 English
VOLUNTARY ANNOUNCEMENT - ANNOUNCE PRELIMINARY CLINICAL DATA OF NEOADJUVANT THERAPY OF CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) FOR MSI-H ADVANCED SOLID TUMORS
Regulatory Filings
2020-12-01 English
VOLUNTARY ANNOUNCEMENT - EARLY COMPLETION OF PATIENT SCREENING FOR ENROLLMENT IN A PIVOTAL PHASE II CLINICAL TRIAL FOR THE CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) FOR TREATING PATIENTS SU
Regulatory Filings
2020-12-01 English
VOLUNTARY ANNOUNCEMENT - EARLY COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICAL TRIAL FOR EBRONUCIMAB (PCSK9 INHIBITORS) FOR TREATING PATIENTS SUFFERING FROM HIGH- OR VERY HIGH-RISK HYPERCHOLEST
Regulatory Filings
2020-11-30 English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR PHASE Ib CLINICAL TRIAL OF IL-4R MONOCLONAL ANTIBODY (AK120) FOR TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN THE UNITED STATES
Regulatory Filings
2020-11-30 English
VOLUNTARY ANNOUNCEMENT - FIRST-IN-HUMAN CLINICAL STUDY PROGRESS OF ANTI-CD47 MONOCLONAL ANTIBODY (AK117) PRESENTED AT SITC 2020
Regulatory Filings
2020-11-11 English
VOLUNTARY ANNOUNCEMENT - LATEST INFORMATION REGARDING THE STUDY OF PENPULIMAB (PD-1) FOR TREATMENT OF PATIENTS WITH METASTATIC NASOPHARYNGEAL CARCINOMA WHO HAD PROGRESSED AFTER TWO OR MORE LINES OF C
Regulatory Filings
2020-11-11 English
VOLUNTARY ANNOUNCEMENT - LATEST INFORMATION REGARDING THE STUDY OF PENPULIMAB (PD-1) FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSIC HODGKIN LYMPHOMA PRESENTED AT SITC 2020
Regulatory Filings
2020-11-11 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2020
Regulatory Filings
2020-11-05 English
VOLUNTARY ANNOUNCEMENT - LATEST INFORMATION REGARDING THE CLINICAL RESEARCH PROGRESS OF CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY)
Regulatory Filings
2020-11-02 English
VOLUNTARY ANNOUNCEMENT - LATEST INFORMATION REGARDING THE PHASE Ia CLINICAL RESEARCH PROGRESS OF PD-1/VEGF BI-SPECIFIC ANTIBODY (AK112)
Regulatory Filings
2020-11-02 English
VOLUNTARY ANNOUNCEMENT LATEST INFORMATION REGARDING SIX STUDIES OF ITS PRODUCTS WILL BE PRESENTED AT SITC 2020, INCLUDING TWO STUDIES TO BE PRESENTED AS LBA
Regulatory Filings
2020-10-27 English
VOLUNTARY ANNOUNCEMENT APPOINTMENT OF DR. JASON NI AS SENIOR VICE PRESIDENT OF THE MEDICAL DEPARTMENT
Regulatory Filings
2020-10-27 English
VOLUNTARY ANNOUNCEMENT SUCCESSFUL DOSING OF THE FIRST HEALTHY SUBJECT WITH CD73 MONOCLONAL ANTIBODY (AK119) IN A TRAIL INTENDED TO TREAT COVID-19 PATIENTS IN NEW ZEALAND
Regulatory Filings
2020-10-26 English
VOLUNTARY ANNOUNCEMENT PENPULIMAB (PD-1) OBTAINED FAST TRACK DESIGNATION FROM FDA FOR THIRD-LINE TREATMENT OF PATIENTS WITH METASTATIC NASOPHARYNGEAL CARCINOMA
Regulatory Filings
2020-10-26 English
VOLUNTARY ANNOUNCEMENT SUCCESSFUL DOSING OF THE FIRST PATIENT WITH IL-4R MONOCLONAL ANTIBODY (AK120) FOR TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN PHASE Ib CLINICAL TRIAL
Regulatory Filings
2020-10-16 English
VOLUNTARY ANNOUNCEMENT - PD-1/CTLA-4 BI-SPECIFIC ANTIBODY NOVEL DRUG (AK104) TREATING RELAPSED OR METASTATIC CERVICAL SQUAMOUS CELL CARCINOMA INCLUDED IN "BREAKTHROUGH THERAPY DESIGNATION&qu
Regulatory Filings
2020-10-12 English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT IN PHASE III CLINICAL TRIAL IN COMBINATION WITH CHEMOTHERAPY FOR 1L METASTATIC SQUAMOUS NSCLC WITH PENPULIMAB (ANTI-PD-1 mAb)
Regulatory Filings
2020-10-12 English
VOLUNTARY ANNOUNCEMENT - REGISTRATIONAL CLINICAL TRIAL FOR 3L NPC WITH PENPULIMAB (PD-1) REACHING KEY ENDPOINTS
Regulatory Filings
2020-10-12 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2020
Regulatory Filings
2020-10-06 English
VOLUNTARY ANNOUNCEMENT - ORAL PRESENTATION AT ESMO2020 REGARDING THE LATEST INFORMATION OF PD-1/CTLA-4 BI-SPECIFIC ANTIBODY NOVEL DRUG (AK104) FOR TREATING ADVANCED MESOTHELIOMA
Regulatory Filings
2020-09-23 English
2020 INTERIM REPORT
Regulatory Filings
2020-09-17 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2020
Regulatory Filings
2020-09-04 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Regulatory Filings
2020-08-19 English
ANNOUNCEMENT - CHANGE OF NON-EXECUTIVE DIRECTORS
Regulatory Filings
2020-08-19 English
VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE SHARES OF THE COMPANY AS A CONSTITUENT STOCK OF 13 HANG SENG INDEX SERIES, INCLUDING HANG SENG COMPOSITE INDEX AND HANG SENG STOCK CONNECT HONG KONG INDEX
Regulatory Filings
2020-08-18 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2020
Regulatory Filings
2020-08-17 English
VOLUNTARY ANNOUNCEMENT - PD-1/CTLA-4 BI-SPECIFIC ANTIBODY NOVEL DRUG (AK104) OF THE COMPANY OBTAINED FAST TRACK DESIGNATION FROM FDA FOR TREATING ADVANCED CERVICAL CANCER
Regulatory Filings
2020-08-13 English
VOLUNTARY ANNOUNCEMENT - PD-1/VEGF (AK112) OBTAINED INVESTIGATIONAL NEW DRUG (IND) APPROVAL FROM NMPA FOR ADVANCED SOLID TUMOR IN CHINA
Regulatory Filings
2020-08-11 English
DATE OF BOARD MEETING
Regulatory Filings
2020-08-05 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2020
Regulatory Filings
2020-08-05 English
VOLUNTARY ANNOUNCEMENT - RESULTS FROM CLINICAL TRIALS OF PD-1/CTLA-4 BISPECIFIC ANTIBODIES FOR MESOTHELIOMA PATIENTS WHO ARE RELAPSED OR REFRACTORY TO STANDARD THERAPIES WILL BE PRESENTED ORALLY
Regulatory Filings
2020-08-03 English
VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF DR. MICHAEL (CHEN) CHEN AS BUSINESS DEVELOPMENT VICE PRESIDENT
Regulatory Filings
2020-07-30 English
VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF DR. ZHANG XINFENG AS SENIOR VICE PRESIDENT
Regulatory Filings
2020-07-17 English
VOLUNTARY ANNOUNCEMENT - SUCCESSFUL DOSING OF THE FIRST PATIENT WITH PD-1/CTLA-4 BISPECIFIC ANTIBODY NOVEL DRUG AK104 IN COMBINATION WITH LENVATINIB FOR FIRST-LINE TREATMENT FOR FINAL STAGE HCC P
Regulatory Filings
2020-07-16 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2020
Regulatory Filings
2020-07-06 English
VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF PROFESSOR BRADLEY J. MONK AT THE UNIVERSITY OF ARIZONA AS LEAD GYNECOLOGIC ONCOLOGY ADVISOR
Regulatory Filings
2020-06-24 English
VOLUNTARY ANNOUNCEMENT SUCCESSFUL DOSING OF THE FIRST FINAL STAGE CA PATIENT WITH AK109 IN CHINA
Regulatory Filings
2020-06-17 English
VOLUNTARY ANNOUNCEMENT SUCCESSFUL DOSING OF THE FIRST PATIENT WITH IL-4R MONOCLONAL ANTIBODY NEW DRUG AK120
Regulatory Filings
2020-06-16 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2020
Regulatory Filings
2020-06-03 English
VOLUNTARY ANNOUNCEMENT - SUCCESSFUL DOSING OF THE FIRST PATIENT WITH INDEPENDENTLY DEVELOPED IL-17A MONOCLONAL ANTIBODY NEW DRUG AK111
Regulatory Filings
2020-06-03 English
INSIDE INFORMATION - NMPA ACCEPTANCE OF THE NEW DRUG APPLICATION OF PENPULIMAB INJECTION
Regulatory Filings
2020-05-26 English
VOLUNTARY ANNOUNCEMENT - PD-1/CTLA-4 BI-SPECIFIC ANTIBODY NOVEL DRUG (RESEARCH CODE: AK104) OBTAINED APPROVAL FROM NMPA TO INITIATE A REGISTRATIONAL TRIAL FOR THIRD-LINE TREATMENT OF PATIENTS WIT
Regulatory Filings
2020-05-21 English
Next Day Disclosure Return
Regulatory Filings
2020-05-20 English
VOLUNTARY ANNOUNCEMENT - ABSTRACTS ON RESULTS FROM CLINICAL TRIALS OF Anti-PD-1 Penpulimab IN COMBINATION WITH ANTI-ANGIOGENIC INHIBITOR ANLOTINIB FOR 1L HCC ACCEPTED FOR POSTER PRESENTATION AT 2020 A
Regulatory Filings
2020-05-19 English
FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD
Regulatory Filings
2020-05-17 English
VOLUNTARY ANNOUNCEMENT-AK101 INVESTIGATIONAL NEW DRUG (IND) APPLICATION APPROVAL FOR ULCERATIVE COLITIS IN CHINA
Regulatory Filings
2020-05-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2020
Regulatory Filings
2020-05-07 English
List of Directors and their Roles and Functions
Regulatory Filings
2020-04-23 English
Terms of Reference of the Remuneration Committee
Regulatory Filings
2020-04-23 English
Terms of Reference of the Nomination Committee
Regulatory Filings
2020-04-23 English
Terms of Reference of the Audit Committee
Regulatory Filings
2020-04-23 English
Fourth Amended and Restated Memorandum and Articles of Association
Regulatory Filings
2020-04-23 English
ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS
Regulatory Filings
2020-04-23 English
WHITE APPLICATION FORM
Regulatory Filings
2020-04-15 English
CLARIFICATION ANNOUNCEMENT
Regulatory Filings
2020-04-15 English
GREEN APPLICATION FORM
Regulatory Filings
2020-04-14 English
YELLOW APPLICATION FORM
Regulatory Filings
2020-04-14 English
WHITE APPLICATION FORM
Regulatory Filings
2020-04-14 English
GLOBAL OFFERING
Regulatory Filings
2020-04-14 English
GLOBAL OFFERING
Regulatory Filings
2020-04-14 English
PHIP (1st submission)
Audit Report / Information FY 2019
2020-04-06 English
PHIP (1st submission)
Regulatory Filings
2020-04-06 English
Application Proof (1st submission)
Audit Report / Information FY 2019
2020-02-03 English
Application Proof (1st submission)
Regulatory Filings
2020-02-03 English